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Since the beginning of this century, only 14 new antibiotics 
have been approved for use in human medicine (Table I). Still-
unmet needs include mainly the so-called ESKAPE pathogens 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneu-
moniae, Acinetobacter baumannii, Pseudomonas aeruginosa, 
Enterobacter spp.), which remain difficult to treat because they 
have accumulated resistance mechanisms to most of the antibi-
otics available so far. Global initiatives have been raised to try 
stimulating research and investment in the field of antibiotic 
development, like the ‘10 x ‘20 Initiative’ (1) from the Infectious 
Disease Society of America (http://www.idsociety.org/10x20/) 
or the ‘Innovative Medicine Initiative’ (http://www.imi.europa.
eu/) from the European Union. At this stage, a series of mole-
cules are in the late stages of clinical development (2,3), many of 
them being essentially new molecules in existing classes, which 
display, however, better properties in terms of intrinsic activity, 
reduced susceptibility to resistance mechanisms, and improved 
pharmacokinetic or safety profiles. This paper will focus on 
those families that count molecules in phase III of clinical de-
velopment, namely lipoglycopeptides (oritavancin), ketolides 
(solithromycin), and quinolones (nemonoxacin; delafloxacin). 
It will explain the prevailing rationale in the development of 
these antibiotics and examine their current pharmacological 
profile based on available clinical data.
Lipoglycopeptides: focus on oritavancin
Lipoglycopeptides are a subclass within the glycopeptide anti-
biotics, which all possess a lipophilic tail attached to the amino 
sugar substituting the cyclic heptapeptide core. Teicoplanin, 
introduced in the clinics in Europe in 1988, is a natural represen-
tative of this subclass. More recently, semi-synthetic derivatives 
were produced, among which telavancin has been on the market 
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Key messages
New antibiotics in the classes of lipoglycopeptides, ketolides,  •
and quinolones are in the late stages of clinical development, 
mainly for the treatment of acute bacterial infections of skin 
and skin structures and/or of the respiratory tract.
These molecules mainly address the problem of resistance  •
in Gram-positive bacteria; their dose has been rationally 
established based on pharmacokinetic/pharmacodynamic 
concepts in order to optimize the chance of therapeutic 
success while at the same time avoiding the risk of selection 
of resistance.
They all presented a satisfactory safety profile in clinical trials,  •
which should be further documented upon administration 
to larger patient populations.
Lipoglycopeptide, ketolide, and quinolone antibiotics are currently 
in clinical development, with specific advantages over available 
molecules within their respective classes. The lipoglycopeptide 
oritavancin is bactericidal against MRSA, vancomycin-resistant 
enterococci, and multiresistant Streptococcus pneumoniae, and 
proved effective and safe for the treatment of acute bacterial 
skin and skin structure infection (ABSSSI) upon administration 
of a single 1200 mg dose (two completed phase III trials). The 
ketolide solithromycin (two phase III studies recruiting for 
community-acquired pneumonia) shows a profile of activity 
similar to that of telithromycin, but in vitro data suggest a lower 
risk of hepatotoxicity, visual disturbance, and aggravation of 
myasthenia gravis due to reduced affinity for nicotinic receptors. 
Among quinolones, finafloxacin and delafloxacin share the 
unique property of an improved activity in acidic environments 
(found in many infection sites). Finafloxacin (phase II completed; 
activity profile similar to that of ciprofloxacin) is evaluated for 
complicated urinary tract and Helicobacter pylori infections. 
The other quinolones (directed towards Gram-positive 
pathogens) show improved activity on MRSA and multiresistant 
S. pneumoniae compared to current molecules. They are in 
clinical evaluation for ABSSSI (avarofloxacin (phase II completed), 
nemonoxacin and delafloxacin (ongoing phase III)), respiratory 
tract infections (zabofloxacin and nemonoxacin (ongoing 
phase  III)), or gonorrhea (delafloxacin).
Key words: Avarofloxacin, delafloxacin, EDP-322, finafloxacin, 
oritavancin, nemonoxacin, solithromycin, zabofloxacin
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2 F. Van Bambeke  
since 2009, dalbavancin has been approved by the FDA in May 
2014, and oritavancin is in the late phase of development.
The rationale for the development of these drugs was to cope 
with vancomycin resistance, which spread in enterococci mainly 
in the USA at the end of the 1980s.
Vancomycin’s mode of action consists in an inhibition of 
the late stages of peptidoglycan synthesis (4, and references 
cited herein). The cyclic heptapeptide core of the molecule 
establishes non-covalent interactions with the D-alanyl-D-
alanine termini of the pentapeptide moiety of lipid II. The 
resulting steric hindrance around these termini prevents the 
access of enzymes that are needed for cross-linking peptido-
glycan precursors via transglycosylation and transpeptidation 
reactions. As a result, vancomycin is slowly bactericidal, with 
a spectrum of activity limited to Gram-positive bacteria, be-
cause its large size prevents it from crossing the outer mem-
brane of Gram-negative bacteria. Two resistance mechanisms 
have emerged over the years (4, and references cited herein). 
The first one, mainly found in enterococci, consists in the ac-
quisition of genes allowing for the synthesis of alternative cell 
wall precursors ending in D-alanyl-D-lactate or in D-alanyl-
D-serine, which show a reduced affinity for vancomycin. At 
the present time, the prevalence of this resistance mechanism 
in enterococci collected from infection sites culminates in the 
USA, reaching 14% (E. faecalis) to 88% (E. faecium) (5) versus 
about 10% in Europe but with huge variations among coun-
tries (6), 15% in Latin America (7), 2% (E. faecalis) to 18% (E. 
faecium) in Canada (8), and, quite surprisingly, low levels of 
resistance ( 5%) in Asia (9). Worryingly, a few cases of gene 
transfer to multidrug-resistant MRSA (methicillin-resistant 
S. aureus) were reported (13 in the USA and a few in other 
countries (10), including in important epidemic lineages like 
US100, US300, and US800). Fortunately, the biological cost of 
this resistance mechanism is high in MRSA, which may help 
preventing its spread (11). Another mechanism of resistance 
emerged in staphylococci, which actually rather confers a 
moderate level of resistance (VISA phenotype; vancomycin-
intermediate Staphylococcus aureus). The molecular mecha-
nism thereof is still poorly understood, but it manifests itself 
by a thickening of the cell wall, in which vancomycin becomes 
unable to saturate the large number of free D-alanyl-D-alanine 
termini. These strains are usually cross-resistant to the lipo-
peptide daptomycin (12), which needs to cross the cell wall to 
access its target in the bacterial membrane. Heteroresistance 
to vancomycin is also common in S. aureus and corresponds 
to the presence of subpopulations of bacteria with reduced 
susceptibility to vancomycin. Heteroresistance or intermediate 
resistance is associated with higher risk of therapeutic failure 
(13). The prevalence of these strains is controversial because of 
the difficulty to detect them correctly.
In this context, early work from Eli Lilly demonstrated that 
chloroeremomycin, which differs from vancomycin by the ste-
reochemistry of the sugar substituting the ring 4 amino-acid 
and by the presence of an additional L-4-epi-vancosamine, 
displayed enhanced activity, including against vancomycin-
resistant strains, possibly due to dimerization facilitating a 
co-operative binding to the target (14). In parallel, deriva-
tives of vancomycin substituted by an alkyl side chain on their 
vancosamine sugar showed also enhanced activity on resis-
tant strains (15). Combining these two features, oritavancin 
(initially LY333328; Eli Lilly, Indianapolis, IN, USA) was first 
described in 1996 (16) as the chlorobiphenylmethyl side chain 
analog of chloroeremomycin (Figure 1). As compared to van-
comycin, this antibiotic shows higher intrinsic activity (lower 
MICs) (Table II) against susceptible Gram-positive organisms, 
as well as against staphylococci displaying the VISA phenotype 
or even against VRE (vancomycin-resisitant enterococci) or 
VRSA (vancomycin-resistant S. aureus) (17,18). This can be 
explained by a dual mode of action (see for review 19), which 
combines an inhibition of transpeptidase and transglycosylase 
activity with an alteration of membrane integrity (20) caused 
by the anchoring of the lipophilic side chain in the bilayer (21). 
Importantly also, this novel mode of action confers to orita-
vancin a rapid and intense bactericidal character, as well as a 
maintained activity on slow-growing bacteria or on biofilms 
(22). Among the other remarkable features of this molecule, 
one should mention its prolonged half-life (terminal half-life 
 360 h), which can be attributed to both a high protein bind-
ing (85%–90%) (4) and an exceptional capacity to accumulate 
within eukaryotic cells (23), reaching concentrations as high 
as 560 mg/L in alveolar macrophages of healthy adults having 
received a cumulative dose of 4 g (24) (Table III). Coupled to 
the bactericidal character of the drug, this high accumulation 
confers to oritavancin a high efficacy against intracellular bac-
teria, including small colony variants of S. aureus, which are 
generally particularly recalcitrant to antibiotic action (25,26).
Oritavancin demonstrated its therapeutic interest in early 
phase II–III clinical trials, where it proved as effective as com-
parators for the treatment of complicated skin and soft tissue 
infections caused by Gram-positive bacteria including MRSA 
(oritavancin 1.5 or 3 mg/kg once daily for 3–7 days versus 
15 mg/kg twice daily for 3–7 days followed by oral cephalexin 
for up to 10–14 days), and for the treatment of S. aureus-associ-
ated bacteremia (5–10 mg/kg oritavancin once daily for 10–14 
Table I. Antibiotics approved by the FDA and the EMA since 2000.
Date of approval
Molecule Antibiotic class FDA EMA
Linezolid oxazolidinone April 2000 (decentralized procedure; ∼ 2001)
cefditoren pivoxil b-lactam August 2001 (available in specific countries)
Ertapenem b-lactam November 2001 April 2004
Gemifloxacin fluoroquinolone April 2003 Not available
Daptomycin lipopeptide September 2003 January 2006
Telithromycin ketolide April 2004 July 2007
Tigecycline glycylcycline 2005 April 2006
Retapamulin pleuromutilin April 2007 May 2007
Doripenem b-lactam October 2007 July 2008
Telavancin lipoglycopeptide September 2009 September 2009
Ceftaroline b-lactam November 2010 August 2012
Fidaxomicin fluoroquinolone May 2011 December 2011
Dalbavancin lipoglycopeptide May 2014 Not yet approved
Tedizolid oxazolidinone June 2014 Not yet approved
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 Renaissance of antibiotics 3
days versus vancomycin 15 mg/kg twice daily or a beta-lactam 
for 10–14 days) with no evidence of increased incidence of side 
effects (see (27) for review). Yet its development was slowed 
down by successive changes in companies (from Eli Lilly to 
Intermune Inc., San Francisco, CA (2002), to Targanta Therapeu-
tics Corporation, Montreal, Quebec (2006), to The Medicines 
Companies, Parsippany, NJ (2009) (28)). A first application to 
the Food and Drug Administration (FDA) in 2009 was unsuc-
cessful, with a request for an additional phase III trial with more 
MRSA-infected patients as well as further evaluation of orita-
vancin effects on macrophage functions, in relation to the huge 
cellular accumulation of the drug. In vitro data documented that 
the drug could indeed cause a mixed storage disorder in lyso-
somes (29) as well as inhibition of latex bead phagocytosis (30), 
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Figure 1. Chemical structure of oritavancin as compared to vancomycin. Major changes are highlighted together with their main consequences for activity 
or pharmacokinetics.
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4 F. Van Bambeke  
affinity for methylated ribosomes to inhibit protein synthesis 
effectively in macrolide-resistant strains. Moreover, the absence 
of cladinose makes them unable to induce methylase pro-
duction (45). Ketolides are also less subject to active efflux by 
Streptococcus pneumoniae while remaining extruded by S. pyo-
genes (39,46). Taken together, these properties insured a renewed 
interest for these antibiotics in the treatment of respiratory tract 
infections (39). Telithromycin is the only ketolide on the market 
since 2001 in Europe and 2004 in the US. Yet, its use has been 
drastically reduced since 2007 because rare but severe side ef-
fects were reported, leading to the addition of warnings to the 
summary of product characteristics (47,48), advising of a risk of 
acute hepatic failure and severe liver injury, as well as of visual 
disturbance, transient loss of consciousness, and life-threatening 
respiratory failure in patients with myasthenia gravis. It has been 
suggested that these adverse effects could result from a blockade 
of nicotinic acetylcholine receptors present at the vagus nerve 
innervating the liver, the ciliary ganglion of the eye, and at the 
neuromuscular junction, thanks to the pyridine-imidazole group 
present on the side chain of telithromycin (49).
A series of other molecules are currently in clinical develop-
ment (Figure 2), which belong to three subfamilies (50), namely 
11-N ketolides, including fluoroketolides like solithromycin, 6-O 
ketolides, such as cethromycin, and bridged bicyclic ketolides like 
modithromycin (EDP-420) or EDP-322 (developed as its EDP-
788 prodrug).
Cethromycin (Abbott compound ABT-773, further developed 
by Advanced Life Sciences, Inc., Woodridge, IL, USA) completed 
two phase III trials where it was compared at a dose of 300 mg QD 
to clarithromycin (250 mg BID) for the treatment of community-
acquired pneumonia (51). However, it was denied by the FDA in 
2009, being considered as safe but not effective enough to justify 
its marketing, as it essentially showed equivalence to clarithro-
mycin (52).
The Enanta Pharmaceuticals (Watertown, MA, USA) com-
pound modithromycin entered phase II clinical trials in 2006 
but has now been supplanted by EDP-322, which is at the present 
time in phase I. While modithromycin was essentially studied 
in vitro and in vivo as an antipneumococcal drug (53–55), EDP-
322 is rather positioned as a potent anti-MRSA agent.
The fluoroketolide solithromycin (CEM-101; Cempra Inc., 
Chapel Hill, NC, USA) is currently recruiting patients for two 
phase III clinical trials where it is compared with oral moxi-
floxacin for the treatment of community-acquired pneumonia. 
As compared to telithromycin, solithromycin may offer an im-
proved safety profile. Since its side chain does not possess the 
pyridine-imidazole group of telithromycin, it is a 30-times less 
potent inhibitor of nicotinic receptors than telithromycin (49). 
Accordingly, none of the rare adverse effects of telithromycin 
had been observed in current phase I/II trials with solithromy-
cin (56). With respect to its mode of action, solithromycin, as 
other ketolides, remains capable of binding to ribosomes that 
are mono- or even dimethylated, thanks to three structural fea-
tures. First, the absence of cladinose gives more movement free-
dom to the desosamine sugar and allows repositioning of the 
antibiotic in the ribosomal binding site. This avoids the steric 
clash between the antibiotic and the dimethylated A2058 that 
explains poor binding of conventional macrolides to dimethy-
lated ribosomes and subsequent resistance. Second, the addi-
tional aryl-alkyl side chain can interact with a base pair formed 
by A752 and U2609 in the 23S RNA from both native and 
methylated ribosomes, further contributing to strengthen the 
antibiotic binding to ribosomes from susceptible and resistant 
strains. Third, the 2-fluorine substituent, which is not present 
but at concentrations far higher than those observed in alveolar 
macrophages from treated volunteers. Moreover, no changes 
in bacterial phagocytosis, killing capacities, or reactive oxygen 
species production were observed in conditions mimicking 
human exposure (30,31), ruling out a major risk of toxicity as-
sociated to the cellular tropism of the drug. New phase III trials 
were designed (Table IV), in which the therapeutic scheme was 
revisited based on recently acquired pharmacodynamic data 
favoring the administration of a single dose of 1200 mg. The 
main arguments supporting this unique administration are the 
concentration-dependent bactericidal character of the drug and 
its prolonged half-life (32). The corresponding pharmacokinetic 
data are illustrated in Table III, highlighting a high free Cmax 
and prolonged terminal half-life (33). A pilot phase II trial sup-
ported this concept (34). It demonstrated that the clinical re-
sponse was better in patients with acute bacterial skin and skin 
structure infections treated by a single 1200 mg dose or 800 mg 
on day 1 followed by 400 mg on day 5 than in those receiving a 
conventional daily administration of 200 mg for 3–7 days, with 
no sign of adverse events. Interestingly enough, this therapeutic 
scheme would be compatible with outpatient parenteral antimi-
crobial therapy (35,36), which is associated with many benefits 
(improved quality of life, reduced costs and risks of nosocomial 
infections). Preliminary reports from these recent phase III 
studies were released and show equivalent efficacy for a single 
1200 mg dose of oritavancin as for a 7–10-day treatment with 
vancomycin (15 mg/kg BID) (37,38), with no sign of side effects. 
The US FDA has accepted a new drug application for oritavan-
cin with priority review, with action date scheduled for 6 August 
2014. On its side, the European Medicines Agency (EMA) has 
accepted for review a marketing authorization application in 
February 2014.
Ketolides: focus on solithromycin
Ketolides are a subclass of macrolide antibiotics characterized 
by the absence of a 3-O-cladinose sugar (replaced by a keto 
group), a 11,12- or 6,11-cyclic moiety, and a heteroaryl-alkyl 
side chain attached to the macrocyclic ring through a suitable 
linker (39). They show an improved activity against strains re-
sistant to conventional macrolides. Macrolides inhibit protein 
synthesis by binding to the domain V of the 50S ribosomal 
subunit and preventing elongation of the peptidic chain. The 
main mechanism of resistance consists in the methylation of 
the ribosomal subunit at the position A2058, which consider-
ably reduces the affinity of the antibiotic for its target by cre-
ating steric hindrance at the antibiotic binding site. Another 
mechanism of resistance consists in the expression of efflux 
systems, which reduce the intrabacterial concentration of the 
drug. The latter mechanism is responsible for the intrinsic 
resistance of most Gram-negative bacteria to macrolides and 
is also associated to acquired, inducible resistance in Gram-
positive bacteria, mainly in streptococci. Macrolide resistance 
is widely spread over the world, reaching 25% in the US (40), 
70% in Asia with still higher figures in specific counties (41), 
and ranging from 50% (Malta) to less than 5% (The Nether-
lands, Norway, Latvia) in Europe, with intermediate values in 
most countries (5%–10% in seven countries, 10%–25% in eight 
countries, and 25%–40% in nine countries) (42). Worryingly 
also, resistance is emerging and spreading in bacteria respon-
sible for sexually transmitted diseases for which macrolides 
often represent a first choice (43,44).
By their additional side chain, ketolides bind to both domains 
V and II of the ribosomal subunit, so that they keep sufficient 
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 Renaissance of antibiotics 5
Table II. Susceptibility of relevant pathogens to antibiotics in development and their comparators.
Species Phenotype Antibiotic MIC50 (mg/L) MIC90 (mg/L) MIC range (mg/L) Reference a
S. aureus MRSA—all vancomycin 1
1
1
1
1
 0.12–2
0.5–2
  0.25–2
(18)
(143)
(144)
oritavancin 0.03
0.06
0.06
0.12
0.12
 0.008–0.5
0.015–0.25
  0.004–4
(18)
(143)
(144)
erythromycin  2
  4
 2
  4
 0.25– 2
0.25– 4
(145)
(65)
clarithromycin 0.25
  8
 128
  8
0.25– 128
  0.12– 8
(146)
(147)
cethromycin 0.03
  0.002
0.03
  0.002
0.015–0.12
  0.002–0.125
(146)
(147)
solithromycin 0.06
0.12
 4
  16
0.03– 4
0.03– 16
(145)
(65)
levofloxacin 8 32 0.03– 32 (129)
moxifloxacin 4
0.125
16
4
0.03– 64
0.03–8
(112)
(127)
zabofloxacin 2 4 0.008–32 (112)
delafloxacin 0.125
0.03
0.5
0.5
 0.004–16
0.008–1
(129)
(127)
hVISA vancomycin 2 1–2 (148)
oritavancin 1 0.12–2 (148)
VISA vancomycin 4 8
8
4–8
4–8
(143)
(148)
oritavancin 1 2
2
0.25–2
0.5–4
(143)
(148)
erythromycin  4  4  4 (65)
solithromycin  16  16 0.06– 16 (65)
nemonoxacin 0.5 2 0.03–8 (149)
VRSA vancomycin  64  64 32– 64 (143)
oritavancin 0.5 1 0.25–1 (143)
MRSA ML-R erythromycin  512  512  512 (150)
cethromycin  64  64  64 (150)
MRSA FQ-S moxifloxacin 0.06
0.06
0.06
0.03/0.25b
0.12
0.06
0.06
0.125/0.5
0.06–0.25
  0.015–0.12
0.03–0.12
0.06–0.125/0.25–0.5
(116)
(151)
(152)
(101)
finafloxacin 0.125/0.06 0.25/0.125 0.125–0.25/0.06–0.125 (101)
zabofloxacin 0.031 0.125 0.016–1 (153)
avarofloxacin  0.008  0.008  0.008–0.015 (152)
nemonoxacin 0.03
0.03
0.06
0.06
 0.008–0.12
  0.008–0.06
(116)
(151)
delafloxacin 0.008–0.03 (154)
MRSA FQ-R moxifloxacin 8
4
4
4
2/8
16
4
8
  16
32 / 32
1–16
0.12–8
0.25– 16
1– 16
2–32/0.5–64
(116)
(151)
(155)
(152)
(101)
finafloxacin 2/1 16 / 4 0.25–32/0.25–32 (101)
zabofloxacin 2 32 0.016–64 (153)
avarofloxacin 0.25
0.25
0.25
1
0.015–2
0.12–4
(155)
(152)
nemonoxacin 0.5
4
1
1
16
1
0.5–1
0.25–64
0.06–4
(149)
(116)
(151)
delafloxacin 0.5–2 (154)
E. faecium VAN-S vancomycin
1
1
1
0.03–4
0.25–4
(144)
(156)
oritavancin
 0.008
0.03
  0.008
 0.0005–0.25
  0.008–0.03
(144)
(156)
erythromycin  4  4  0.12– 4 (65)
solithromycin 0.25 2 0.03–2 (65)
nemonoxacin 4 4 0.06–8 (149)
VAN-R vancomycin  64
  16
 64
  256
8– 256
  256
 16
(17)
(144)
(156)
oritavancin 0.015
0.03
0.06
0.25
0.06
 0.0005–1
  0.008–0.25
(17)
(144)
(156)
erythromycin  4  4 0.25– 4 (65)
solithromycin 2 2 0.25–2 (65)
nemonoxacin 4 16 0.06–16 (149)
S. pneumoniae all vancomycin 0.25  0.06–0.5 (144)
(Continued)
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6 F. Van Bambeke  
Table II. (Continued)
Species Phenotype Antibiotic MIC50 (mg/L) MIC90 (mg/L) MIC range (mg/L) Reference a
oritavancin 0.008  0.0005–0.5 (144)
clarithromycin 0.06
0.25
 128
64
0.03– 128
0.004–64
(146)
(72)
cethromycin 0.015 0.12 0.008–16 (146)
solithromycin 0.015 0.06 0.002–1 (72)
moxifloxacin 0.12
0.5
0.25
1
0.008– 8
0.125–0.5
(105)
(101)
finafloxacin 1 2 0.5–4 (101)
zabofloxacin 0.015
0.063
0.03
1
0.015–0.06
0.008–4
(112)
(153)
avarofloxacin 0.008 0.015  0.004–1 (105)
S moxifloxacin 0.12
0.12
0.5
0.25
0.12
0.5
0.03–0.25
0.06–0.25
0.125–0.5
(157)
(151)
(112)
zabofloxacin 0.016
0.015
0.03
0.03
 0.001–0.06
0.015–0.06
(157)
(112)
nemonoxacin 0.12 0.12 0.06–0.25 (151)
Pen-R vancomycin 0.25 0.25–0.5 (144)
oritavancin 0.008 0.002–0.015 (144)
moxifloxacin 0.12
0.12
0.25
0.25
0.03–0.25
0.06–0.25
(157)
(116)
zabofloxacin 0.016 0.03 0.004–0.03 (157)
nemonoxacin 0.015 0.015 0.015–0.06 (116)
ML-S erythromycin 0.062 0.125 0.015–0.125 (150)
clarithromycin 0.03 0.06 0.015–0.06 (158)
cethromycin  0.007 0.031  0.007–0.31 (150)
solithromycin 0.008 0.015 0.002–0.015 (158)
ML-R vancomycin 0.5 0.12–0.5 (144)
oritavancin 0.25 0.008–0.5 (144)
erythromycin 64  128 1– 128 (150)
clarithromycin 1– 64 (158)
cethromycin 0.031 0.25  0.007–2 (150)
solithromycin 0.015–1 (158)
FQ-R moxifloxacin 2
2
1
4
4
8
16
8
2–8
2– 8
4–16
0.25– 8
(157)
(151)
(155)
(105)
E. coli all ciprofloxacin 0.015
0.063
0.06
0.5
0.5
16
0.008–64
0.008–8
0.06–16
(112)
(153)
(116)
zabofloxacin 0.06
0.125
1
0.5
0.015–64
0.008–32
(112)
(153)
nemonoxacin 0.12 32  0.015– 512 (116)
FQ-S ciprofloxacin 0.016/0.125
0.015
0.03/0.25
0.25
 0.008–0.125/0.06–2
0.08–0.25
0.008–2
(101)
(154)
(155)
finafloxacin 0.125/0 .016 0.25/0.03 0.03–1/ 0.008–0.125 (101)
avarofloxacin 0.06 0.25 0.015–0.5 (155)
delafloxacin 0.016–0.25 (154)
FQ-R ciprofloxacin 128 /  256
64
 256 /  256
256
8– 256 /  256
64– 128
16– 256
(101)
(154)
(155)
finafloxacin 128 / 8 256 / 32 164– 256 / 2–64 (101)
avarofloxacin 4 16 1–16 (155)
delafloxacin 2–128 (154)
Enterobacter 
spp.
ciprofloxacin  0.03/0.125  0.03/0.25  0.03 / 0.06–0.5 (101)
finafloxacin 0.125/ 0.03 0.125/ 0.03 0.06–0.5/ 0.03–0.125 (101)
P. aeruginosa all ciprofloxacin 0.25
0.5
0.25
2
16
0.5
0.002–16
0.06–16
0.125–1
(153)
(116)
(155)
zabofloxacin 1 32 0.016–64 (153)
nemonoxacin 1 32 0.12– 512 (116)
avarofloxacin 1 2 0.5–4 (155)
FQ-S ciprofloxacin 0.25/0.5 0.5 / 1 0.03–1/0.125–2
0.25–2
(101)
(154)
finafloxacin 1 / 0.5 32 / 2 4–16 / 0.25–8 (101)
delafloxacin 0.016–1 (154)
FQ-R ciprofloxacin 64– 128 (154)
delafloxacin 4–32 (154)
S  susceptible; FQ-R  fluoroquinolone-resistant; FQ-S  fluoroquinolone-susceptible; hVISA  heterogenous vancomycin-intermediate S. aureus; 
ML-R  macrolide-resistant; ML-S  macrolide-susceptible; MRSA  methicillin-resistant S. aureus; Pen-R  penicillin-resistant (based in most cases on 
CLSI  (Clinical and Laboratory Standards Institute) susceptibility breakpoints for marketed comparators); VISA  vancomycin-intermediate S. aureus; 
VRSA  vancomycin-resistant S. aureus.
aComparison of MIC distributions among antibiotics should be performed using data from the same bibliographic reference.
bValues in italics: MICs determined at acidic pH (∼5.2).
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 Renaissance of antibiotics 7
bly, no influence on the QTc interval was observed so far (56). 
A phase II clinical trial is examining the efficacy of a single dose 
for the treatment of uncomplicated gonorrhea. The drug has 
received the Qualified Infectious Disease Product (QIDP) status 
and Fast Track designation for community-acquired pneumonia 
from the US FDA in September 2013.
Quinolones
Quinolone antibiotics represent one of the largest antibiotic 
classes when considering that already in 2005 about 10,000 
compounds had been patented and 800 million patients had 
been treated (76,77). Fluoroquinolones inhibit bacterial replica-
tion by forming a ternary complex with DNA and class II topoi-
somerases (DNA gyrase and topoisomerase IV), two enzymes 
responsible for DNA supercoiling. Quinolones have been cat-
egorized in successive generations (77–79) based on the nature 
of their substituents, which governs their interaction with their 
pharmacological target and their spectrum of activity (77,79). 
The substituents that best increase potency are a cyclopropyl or, 
alternatively, a difluorophenyl in position 1, a fluorine in posi-
tion 6, and a halogen, methoxy, or fused third ring in position 8 
(Figure 3). Molecules harboring a piperazine-based substituent 
in position 7 are in general more active on Gram-negative bacte-
ria and preferentially target DNA gyrase, while those presenting 
a pyrrolidine-based substituent rather show activity on Gram-
positive bacteria and target topoisomerase IV. Dual targeting 
molecules present a broad spectrum of activity. Nalidixic acid 
(by-product of antimalarial research) is representative of the 
first generation, with only a narrow spectrum, low serum levels, 
and toxicity issues. The second generation is characterized by the 
addition of a fluorine substituent at position 6 (hence the name 
of fluoroquinolones often given to the whole class), which mark-
edly increases activity. Ciprofloxacin is the most widely used 
molecule in this generation and remains one of the most active 
fluoroquinolones on Gram-negative bacteria. Levofloxacin, the 
active isomer of ofloxacin, another second-generation molecule, 
is considered by certain authors as constituting an independent 
generation (78). Moxifloxacin is the leading molecule in the 
next generation, which is characterized by a spectrum of activity 
rather oriented towards Gram-positive bacteria including an-
aerobes (activity on Gram-negative anaerobes like Bacteroides is 
too weak to envision its use for the treatment of intra-abdominal 
infections (80)). Among more recent generations, one can find 
molecules like gemifloxacin (marketed in the US and in Korea), 
which also include Gram-positive anaerobes in their spectrum, 
or garenoxacin (marketed in Japan), which lacks the fluorine 
in position 6, giving rise to the desfluoroquinolones subclass 
(77). Despite the tremendous number of molecules produced, 
only a few of them were brought on the market, among which 
some were withdrawn or have seen their use restricted because 
in telithromycin, may possibly account for the higher intrinsic 
activity of solithromycin as compared to telithromycin (57). As 
for other macrolides and ketolides, solithromycin’s pharmacoki-
netic profile is characterized by a broad tissue distribution and 
high cellular accumulation (58,59), reaching elevated concen-
trations in alveolar macrophages (24-h AUC: 1500 mg.h/L; ratio 
to serum concentration: 180) and epithelial lining fluid (24-h 
AUC: 80 mg.h/L; ratio to serum concentration: 10). Its half-life 
of 6.65 h related to a high protein binding (85%) (60) allows 
for a once-a-day administration, with a proposed therapeutic 
scheme by oral route consisting in a loading dose of 800 mg fol-
lowed by a 4-day treatment with a daily dose of 400 mg. In these 
conditions, serum levels reached a Cmax and an AUC of approx. 
0.8 mg/L and 7 mg.h/L (for a 400 mg dose) (Table III) and of 
approximately 1.3 mg/L and 14 mg.h/L (for an 800 mg dose) 
(60). This scheme allows reaching the pharmacodynamic target 
demonstrated as predictive of efficacy for this drug, namely an 
AUC/MIC  1.3 h in epithelial lining fluid (ELF) (61) with a 
probability of 99.9% for MICs as high as 1 mg/L (62). However, 
a loading dose does not seem necessary when administering the 
drug by intravenous route (63). MIC90 against contemporary iso-
lates of respiratory pathogens were 0.25 mg/L for S. pneumoniae 
(0.5 mg/L for multiresistant strains), 0.015 mg/L for Legionella 
pneumophila, and 0.5 mg/L for Moraxella catarrhalis. As other 
macrolides, solithromycin is less active on Haemophilus influ-
enzae (MIC90 2 mg/L). Nevertheless, all MIC90 values remain 
lower than those recorded for telithromycin (64). Solithromycin 
also shows useful activity against staphylococci and entero-
cocci (65), or pathogens causing sexually transmissible diseases 
(Chlamydia trachomatis (66), Neisseria gonorrhoeae (67–69), 
Mycoplasma spp. (70,71)). Interestingly, solithromycin MICs 
remain low against strains resistant to conventional macrolides 
or to other antibiotic classes (72,73), suggesting it may represent 
a useful alternative to currently recommended drugs in areas 
with high resistance rates. Lastly, solithromycin demonstrates 
activity against biofilms formed by S. pneumoniae (74), which 
may be an advantage when dealing with chronic infections 
where biofilms are thought to play a major role in recurrence of 
the infection. Taken together, these properties are advantageous 
for the treatment of respiratory or genital infections. They also 
rationalize activity against intracellular pathogens like S. aureus, 
Listeria monocytogenes, L. pneumophila, and N. gonorrhoeae 
(58,67), against which solithromycin proves at least as effec-
tive but more potent than other macrolides, based essentially 
on its lower MICs and not on its higher accumulation level. In 
the clinics, solithromycin has, at this stage, already proven as 
effective as levofloxacin with a more favorable safety profile in a 
phase II trial for the treatment of community-acquired bacterial 
pneumonia, where patients were randomized to receive either 
800 mg solithromycin orally on day 1, followed by 400 mg daily 
on days 2 to 5, or 750 mg levofloxacin during 5 days (75). Nota-
Table III. Main pharmacokinetic properties of antibiotics.
Antibiotic Dose and route Cmax (mg/L)a AUC (mg.h/L)a Protein binding (%) T1/2 (h) Tissue/serum conc. ratio References
Oritavancin 1200 mg IV 19.4 (free) 132 85 31.3 (b)
393 (g)
0.03–0.1 (ELF)
1–56 (AM)
(24,33)
Solithromycin 400 mg IV 0.8 7 85 6.6 2.4–28.6 (ELF)
44–515 (AM)
(59,60)
Finafloxacin 800 mg oral 11 28 10 (103)
Avarofloxacin 250 mg oral 2 35 65 14 17–64 (ELF)
74–157 (AM)
(109)
Zabofloxacin 400 mg oral 2 11 (114)
Nemonoxacin 500 mg oral 3.5–5 32 16 10–15 (119,120)
Delafloxacin 300 mg IV 10 24 16 8–12 (132,133)
 ELF  epithelial lining fluid; AM  alveolar macrophages.
aTotal concentration, unless stated otherwise.
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10 F. Van Bambeke  
levels of resistance (91). More anecdotal resistance mechanisms 
include the plasmid-mediated production of the protein Qnr 
that impairs the binding of fluoroquinolones to DNA (92), or 
the N-acetylation of fluoroquinolones harboring a piperidine 
substituent in position 7 (norfloxacin and ciprofloxacin) by an 
AAC(6’)-Ib-cr enzyme originally inactivating aminoglycosides 
(93). As recently reviewed in extenso (94,95), epidemiological 
surveys performed over the globe demonstrate increasing rates 
of fluoroquinolone resistance, but huge discrepancies among 
countries, with the highest figures being observed in the Asia– 
Pacific region and lower ones in Europe and North America. 
Considering resistance to ciprofloxacin in Gram-negative spe-
cies, it can reach more than 20% in uropathogens or bacteria 
causing intra-abdominal infections. Worryingly enough, much 
higher values ( 70%) are reported in enterobacteriaceae dis-
playing other mechanisms of resistance (including production 
of extended-spectrum beta-lactamases (96)) or associated 
with complicated infections. Among enteropathogens, Campy-
lobacter species show the highest resistance rate (80% in some 
reports), but Salmonella and Shigella often harbor plasmid-
mediated resistance and started to spread in the Middle East. 
More than half of Escherichia coli causing traveler’s diarrhea are 
fluoroquinolone-resistant in Asia or Africa. In anaerobes, resis-
tance rates are elevated in some countries (∼50%); selection may 
have occurred after using early-generation fluoroquinolones 
displaying poor antianaerobic activity. Among respiratory tract 
pathogens, Haemophilus influenzae and Moraxella catarrhalis 
remain susceptible while resistance rates in Streptococcus pneu-
moniae are so far usually low ( 4%). Again, at-risk situations 
include elderly patients, nursing homes, or hospitals. In spite of 
of toxicity issues (81). More frequent reasons for withdrawal in-
clude tendinitis (pefloxacin), rash (sparfloxacin, clinafloxacin), 
QTc prolongation (grepafloxacin), dysglycemia (gatifloxacin, 
clinafloxacin), hemolysis (temafloxacin), and hepatotoxic-
ity (trovafloxacin) (77,79,81). Resistance to fluoroquinolones 
is primarily caused by target mutations, which can accumulate 
and lead to high-level resistance. First-step mutations occur in 
general in the primary target enzyme (thus more often in GyrA 
subunit of DNA gyrase in Gram-negative bacteria; ParC subunit 
of topoisomerase IV in Gram-positive bacteria) (77). Yet, this 
may vary depending also on the bacterial species, the reverse 
being notably observed in S. pneumoniae (77,82). Active ef-
flux is contributing to decreased susceptibility as well. Gram-
positive bacteria do express narrow-spectrum pumps extruding 
only fluoroquinolones. NorA was historically described as the 
fluoroquinolone transporter in S. aureus (83), but more recent 
studies suggest a potential role of other efflux pumps in clinical 
isolates, like NorB, NorC, MdeA (84) or the plasmid-encoded 
QacA and QacB (85). In S. pneumoniae, PmrA was the first de-
scribed transporter (86), but the heterodimer PatA/PatB is now 
considered as the main efflux system playing a role in resistance 
of clinical isolates (87). Of note, there are huge differences in the 
recognition of different fluoroquinolones by these pumps, nor-
floxacin and ciprofloxacin being more affected than moxifloxa-
cin, for example (88,89), due to their more hydrophilic character 
and to the absence of a bulky substituent in position 7. In Gram-
negative bacteria, fluoroquinolones are virtually universal sub-
strates of many broad-spectrum transporters (90). By reducing 
intrabacterial concentration of antibiotics, efflux can contribute 
to select target mutations and therefore participate in increasing 
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 Renaissance of antibiotics 11
They all show increased intrinsic activity, including against strains 
resistant to current fluoroquinolones, due to an improved interac-
tion with their target enzymes.
Finafloxacin (BAY35-3377; Bayer HealthCare, Wuppertal, Ger-
many; now developed by MerLion Pharmaceuticals GmbH; Singa-
pore and Berlin, Germany) is an 8-cyano-fluoroquinolone. It has 
the particularity of showing increased bacterial uptake, and there-
fore enhanced activity, at acidic pH (98–100), a condition which 
usually reduces the potency of this class of drugs. This constitutes 
an advantage for the treatment of infections localized in an acidic 
environment like the urinary and genital tracts, the gastric mu-
cosa, the airways of patients suffering from chronic inflammatory 
diseases, or abscesses (99) as well as against intracellular infections 
with phagolysosomal bacteria like S. aureus (98). Finafloxacin 
MICs against ciprofloxacin-susceptible or resistant Gram-negative 
bacteria are similar to those of ciprofloxacin at neutral pH but 
3–5 dilutions lower at pH 5.2 (99–102). It is, however, less active 
than ciprofloxacin on Pseudomonas aeruginosa or other ESKAPE 
pathogens like Klebsiella or Enterobacter spp. (101). In contrast 
to ciprofloxacin, finafloxacin is not a substrate for the fluoroqui-
nolone efflux system by QepA1 of Escherichia coli (possibly related 
to its lower hydrophilicity) and is not affected the AAC(6’)-Ib-cr 
acetylase, as it does not display the piperazine ring substrate for 
this enzyme in position 7 (100). In phase I studies by oral route, 
finafloxacin Cmax was close to 11 mg/L for an 800 mg dose and 
fluoroquinolone contra-indication in pediatrics, resistance has 
been detected in pneumococci isolated from children, possibly 
due to transmission from adults. In Gram-negative pathogens 
causing health care-associated pneumonia, resistance rates 
vary enormously among countries and regions, making local 
surveillance data indispensable. In bacteria causing skin infec-
tions, fluoroquinolone resistance is so common among MRSA 
that current molecules can no more be considered as valuable 
therapeutic options. MSSA (methicillin-susceptible S. aureus) 
remain more susceptible, as well as Streptococcus pyogenes 
(with, however, some local spots of higher resistance, like in 
Belgium (97)). Among pathogens causing sexually transmit-
ted diseases, high variations in resistance rates are observed. 
The more alarming reports concern Neisseria gonorrhoeae, with 
values ranging from 10% in the US to 60% in Europe and more 
than 90% in Asia.
In this context, research of new molecules over the last years 
has focused on the identification of molecules displaying high 
intrinsic activity including against strains resistant to current 
fluoroquinolones. This goal was achieved by in-depth structure– 
activity relationship studies in order to identify the substituents 
that allow a dual targeting of both topoisomerase IV and DNA-
gyrase together with a high binding affinity to these enzymes.
Among the numerous quinolones under study at the present 
time, five new molecules are in clinical development (Figure 3). 
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are on a gray background. Other specific features are highlighted by black arcs.
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Zabofloxacin (DW-224a; Dong Wha Pharmaceuticals Indus-
try, Ltd; Anyang City, Korea) is constructed on a naphthyridone 
nucleus. It presents a cyclopropyl substituent in position 1 and a 
bulky, pyrrolidine-based substituent in position 7, which directs 
its spectrum towards Gram-positive bacteria. It targets both DNA 
gyrase and topoisomerase IV in S. pneumoniae, which reduces 
the risk of selection of resistance (111). It is in general 2–16 times 
more potent than moxifloxacin on Gram-positive bacteria but 
2–4 times less potent than ciprofloxacin against Gram-negative 
bacteria (112). It is also more potent than ciprofloxacin against 
N. gonorrhoeae or C. trachomatis, suggesting it could be an ap-
pealing alternative to ciprofloxacin against macrolide-resistant 
strains (113). A phase I trial evidenced a Cmax of approximately 2 
mg/L and a 24-h AUC of approximately 11 mg.h/L after a single 
oral dose of 400 mg (Table III) (114). A phase II trial compar-
ing zabofloxacin (400 mg QD for 3 or 5 days) to moxifloxacin 
(400 mg QD for 7 days) for the treatment of mild to moderate 
community-acquired pneumonia concluded the clinical and mi-
crobiological cure rates were similar, with no sign of side effects 
(115). A second phase II trial has compared it to levofloxacin 
in the same indication (Table IV). Zabofloxacin is claimed to be 
in late stage of phase III development for respiratory tract in-
fections by Gram-positive resistant bacteria, but no additional 
information has been made available.
Nemonoxacin (TG-873870; TaiGen Biotechnology Co., Ltd., 
Taiwan) is a desfluoroquinolone harboring a methoxy group 
in position 8 and a 6-membered aminated substituent in posi-
tion 6. It is globally 2–8-fold more potent than moxifloxacin 
against most Gram-positive cocci but 4-fold less potent than 
ciprofloxacin against Gram-negative bacilli (116). Additionally, it 
also shows useful activity on Chlamydia spp. (117) or Clostridium 
difficile (118).
In preclinical studies, nemonoxacin was minimally metabo-
lized (less than 5% metabolites recovered) and did not influence 
human hepatic CYP3A4 activity; it had minimal effect on cardiac 
conduction as measured by ECG QTc interval prolongation and a 
low phototoxic potential (119 and references cited therein). Hu-
man pharmacokinetic data for the oral route (Table III) showed a 
Cmax around 3.5–5 mg/L and an AUC of approximately 32 mg.h/L 
for a dose of 500 mg, a low protein binding (16%) but a half-life 
of 10–15 h (longer upon administration of higher doses). This al-
lows for a once-a-day mode of administration while maintaining 
free serum levels about the MIC of target pathogens (119,120). 
AUC was decreased of about 17% by food intake. The most 
common adverse effect observed in phase I was headache (120). 
In vitro pharmacodynamic studies suggest that a 3-log kill could 
be achieved against S. pneumoniae for free AUC/MIC ratio 
 47.5 h21 (121). This is consistent with the globally accepted 
concept that the probability for therapeutic success with qui-
nolones is free AUC/MIC ratio  25–40 h21 for Gram-positive 
bacteria (122). A pharmacodynamic breakpoint of ∼0.5 mg/L 
could be proposed on these bases, which is well above the MIC 
distribution of pneumococci (Table II) and can partly cover 
MRSA. The drug completed two phase II clinical trials with the 
oral formulation for community-acquired pneumonia and dia-
betic foot infection, and one phase II clinical trial with the intra-
venous formulation for community-acquired pneumonia, as well 
as one phase III trial for the treatment of community-acquired 
pneumonia by oral route. The results of one of these trials were 
published (123) and showed that nemonoxacin (750 mg or 500 
mg) orally for 7 days was as effective as levofloxacin (500 mg), 
with 1) clinical success rates close to 90%, 2) bacterial eradication 
of 90% in the 750 mg dose and the levofloxacin groups versus 
85% in the 500 mg dose group, and 3) good tolerability. The US 
an AUC of 28 mg.h/L (Table III). Cmax increased linearly with the 
dose, but AUC normalized to the dose increased of about 50% for 
doses  400 mg, because elimination was slowed down (t1/2 of ap-
proximately 5 h for doses lower than 400 mg and 10 h for higher 
doses). This deviation from linearity is, however, thought to result 
from inaccurate detection of low concentrations (103). Consider-
ing as pharmacodynamic criterion of efficacy an AUC/MIC  125 
h21 for infections caused by Gram-negative bacteria (104), a phar-
macodynamic breakpoint of 0.25 mg/L could be proposed for this 
dose. Yet, the drug can reach much higher concentrations in the 
urine than in serum (103), which may insure its efficacy even for 
less susceptible bacteria, especially if taking into account the acidic 
pH of this fluid. The accumulation of the drug within eukaryotic 
cells (about 5-fold) explains activity on intracellular organisms 
like S. aureus, L. pneumophila, or L. monocytogenes, with a relative 
potency and a maximal efficacy similar to those of ciprofloxacin 
(98). Intracellular potency is, however, improved when cells are 
incubated at acidic pH, because this condition increases the accu-
mulation of the drug within eukaryotic cells as well. The US Food 
and Drug Administration has designated finafloxacin for oral and 
intravenous use as a Qualified Infectious Disease Product and for 
Fast Track development for the treatment of complicated urinary 
tract infections (cUTI) including pyelonephritis, complicated in-
tra-abdominal infections (cIAI), and acute bacterial skin and skin 
structure infections (ABSSSI). It is currently in phase II of clinical 
development (Table IV). Moreover, the drug has also completed 
two phase III trials for the treatment of ear infections using topical 
application, in partnership with Alcon Pharmaceuticals Ltd (Forth 
Worth, TX, USA).
Avarofloxacin (JNJ-Q2; Janssen Pharmaceutica, subdivision 
of Johnson & Johnson, licensed to Furiex Pharmaceuticals, 
Morrisville, NC, USA, in 2011) harbors a cyclopropyl in posi-
tion 1, a methoxy in position 8, and a bulky, 6-membered ami-
nated substituent in position 7, itself substituted by a fluorine. 
Avarofloxacin proves more active than moxifloxacin against 
Gram-positive pathogens, including MRSA or S. pneumoniae 
resistant to fluoroquinolones (Table II). It is also slightly (1–2 
dilutions) more active than moxifloxacin against other respira-
tory pathogens like H. influenzae or M. catarrhalis (105) and 
than ciprofloxacin against N. gonorrhoeae, against which it also 
keeps activity on ciprofloxacin-resistant strains (106). In vitro, 
animal and human data assessing cardiovascular safety disclosed 
a profile comparable to that of moxifloxacin (107). Considering 
that a free AUC/MIC  14 h21 generates a static effect in ani-
mal models of skin infections by S. aureus, PK/PD simulations 
showed a target attainment rate of 0.966 for MIC  0.5 mg/L if 
using the drug at an oral dose of 250 mg or an intravenous dose 
of 150 mg twice daily (108).
This dosage was therefore selected in clinical trials. Pharma-
cokinetic data from phase I (Table III) reported a Cmax of approx. 
2 mg/L, and AUC of 28 mg.h/L and a half-life of approximately 
14 h for an oral dose of 250 mg, with ELF/plasma and alveolar 
macrophages ratios ranging, respectively, between 17 and 64, 
and 74 and 157 (109). A first published report of a phase II study 
showed comparable cure rates for avarofloxacin (150 mg intra-
venously twice daily followed by 250 mg orally twice daily) and 
moxifloxacin (400 mg once daily, intravenously or orally) for 
the treatment of community-acquired infection (110). Yet, the 
number of patients was too small (16 in each arm) to perform in-
depth statistical analyses. Avarofloxacin received a Qualification 
as Infectious Disease Product and Fast Track designation from 
the US FDA in February 2013 and is ready to start phase III trials 
for the treatment of acute bacterial skin and skin-structure infec-
tions and community-acquired pneumonia.
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acute bacterial skin and skin structure infections (ABSSSI) and 
community-acquired bacterial pneumonia (CABP) in October 
2012. It is currently in phase III of clinical development for 
acute bacterial infection of skin and skin structure infection 
and uncomplicated gonorrhea based on its excellent in vitro 
activity against N. gonorrhoeae, including ciprofloxacin-resis-
tant strains (141).
Conclusion
At the end of this survey, one can see that the molecules in the 
last stages of development mainly address the question of re-
sistance in Gram-positive pathogens, among which MRSA and 
VRE belong to the so-called ESKAPE pathogens. Oritavancin 
consistently shows low MIC on VRE, multiresistant pneu-
mococci, MRSA, but also VRSA and, to some extent, VISA. 
Solithromycin and new quinolones (except finafloxacin) bring 
in general an impressive response to resistance to earlier-
generation molecules in staphylococci and pneumococci. 
Some variations do, however, exist among fluoroquinolones, 
with avarofloxacin and delafloxacin being the more potent on 
MRSA. Delafloxacin and finafloxacin display a clear advantage 
for infections located in acidic territories caused, respectively, 
by Gram-positive and Gram-negative bacteria. While being 
the only molecule rather directed towards Gram-negative 
bacteria, finafloxacin does not offer any advantage over cipro-
floxacin on ESKAPE pathogens.
Oritavancin can be considered as a member of a totally new an-
tibiotic class, since its mode of action is clearly different from that 
of conventional glycopeptides. It could usefully complement the 
only marketed molecule in this class, telavancin, by a somewhat 
higher activity on VRSA and VRE and, most conspicuously, by its 
original mode of administration, which clearly offers a series of 
advantages in terms of ease of use and reduction of hospitaliza-
tion duration.
Ketolides and new quinolones essentially offer improved 
intrinsic activity as compared to earlier molecules, which was 
reached by optimizing their binding to the pharmacological 
targets. Hopefully enough, the dose of all of them has be-
ing rationally established based on PK/PD concepts, which 
should help limiting the risk of selection of resistance if used 
appropriately. Yet, we clearly need much more data related 
to their clinical efficacy on multidrug-resistant pathogens 
and their safety profile. For registration, health authorities 
demand at this stage the demonstration of an equivalence 
to standard treatment, which, by definition, prevents the 
investigators from enrolling patients infected by bacteria re-
sistant to the comparator. These resistant strains are indeed 
actually the main targets for the new drugs. The scientific 
community is therefore pushing for the inclusion of non-
comparative trials directed to the evaluation of new anti-
biotics against these specific populations or of superiority 
trials in the development plan of new antibiotics (142). With 
respect to safety issues, experience with previously marketed 
molecules has shown that severe adverse reactions were too 
rare to be detected during clinical development. Post-mar-
keting surveillance is therefore essential. Moreover, one can 
argue that reasonable use, meaning limited to infections suf-
ficiently severe really to require antibiotic treatment, should 
contribute to contain this risk. This would go through the 
establishment of rational and regularly updated guidelines 
for the treatment of bacterial infections in order to preserve 
the interest of these new molecules we are looking forward 
to seeing on the market. 
FDA granted nemonoxacin Qualified Infectious Disease Product 
and Fast Track designations for community-acquired bacterial 
pneumonia (CAP) and acute bacterial skin and skin structure 
infections (ABSSSI) in December 2013.
Delafloxacin (WQ-3034, discovered by Wakunaga Pharma-
ceutical Co., Ltd., Osaka & Hiroshima, Japan; further developed 
as ABT-492, Abbott Park, IL, USA, and then as RX-3341 by 
Rib-X Pharmaceuticals Inc., New Haven, CT, USA; now Melinta 
Therapeutics, New Haven, CT) has the unique property of be-
ing an anionic fluoroquinolone, as it lacks a positively charged 
substituent in position 7. This chemical feature rationalizes why 
it accumulates much more in both bacteria and eukaryotic cells 
at acidic pH (124). Delafloxacin shows very low MICs against 
Gram-positive pathogens, with values typically 4 dilutions lower 
than those of moxifloxacin, even against strains showing elevated 
MIC to the reference drug (124). At acidic pH, the difference in 
potency between the two antibiotics can reach 7 dilutions (124). 
The high potency of delafloxacin is thought to result from the 
specific shape, size, and polarity of the molecule as compared 
to conventional fluoroquinolones (125). Although designed as 
an anti-Gram-positive drug, it is also at least as potent as cipro-
floxacin against Gram-negative bacteria, including P. aeruginosa 
(Table II). Selection of resistance in S. aureus is infrequent (1029 
to 10211), and concentrations preventing the selection of mu-
tations (MPC (126)) range from 1 to 4 times the initial MIC, 
with values 8- to 32-fold lower than for other quinolones (127). 
Delafloxacin also proved active in in vitro models of biofilm or 
intracellular infection by S. aureus (124,128), despite the fact it 
mainly localizes in the cytoplasmic compartment of cells (124). 
This may be due to the high diffusibility of fluoroquinolones, 
which may help them freely to cross biological membranes 
within the cells to gain access to the infected compartment. Ef-
ficacy was further documented in animal models of granuloma 
pouch by Gram-negative bacteria and thigh infection or renal 
abscess by S. aureus (129–131).
In phase I trials (Table III), delafloxacin showed a Cmax of 10 
and 16 mg/L and an AUC of 24 and 40 mg.h/L after IV adminis-
tration of 300 and 450 mg, respectively, with a free fraction of 84% 
and a half-life of 8–12 h (132,133).
Similar values (slightly lower Cmax (7 mg/L)) were observed 
in phase II patients treated for acute bacterial skin and skin 
structure infections by a daily dose of 300 mg intravenous and 
BID (134). Elimination is mainly renal, but metabolites have 
been detected, among which a glucuronoconjugate (135). The 
dose should be reduced from 300 to 200 mg IV in case of renal 
insufficiency (136). Based on a pharmacodynamic target of 
fAUC/MIC  25–40 h21 for Gram-positive infections (122), a 
pharmacodynamic breakpoint of 0.5 mg/L could be proposed, 
which covers most of the strains, including fluoroquinolone-
resistant ones. This is in accordance with PK/PD animal data 
(137) and Monte Carlo simulations, which concluded to a 
 90% target attainment rate for MICs  0.5 mg/L upon ad-
ministration of 300–450 mg BID (133), and rationalizes the 
doses used in phase III trials (Table IV). Safety data available 
so far did not reveal any specific adverse events (132,138), 
including on the cardiac function (no prolongation of QTc 
interval (139)). Published data from phase II clinical trials 
demonstrated equal efficacy in the treatment of acute bacte-
rial infection of skin and skin structure infection (ABSSSI) 
for delafloxacin 300 mg IV BID as compared to linezolid or 
vancomycin but better efficacy when considering as end-point 
a reduction  20% or  30% in lesion size after 48–72 hours 
(138,140). The US FDA has granted delafloxacin the status of 
a Qualified Infectious Disease Product for the indications of 
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